We dive into the world of cutting-edge cancer treatments with Aino Kalervo, Chief Operating Officer of TILT Biotherapeutics and occasional tennis legend in her spare time.TILT recently closed a $25M series B round, backed by leading Finnish investors, to finance the clinical development of its oncolytic virus candidate to supercharge cancer immunotherapies.We also explore the challenging space of oncolytic viruses and the untapped potential of biotech innovation in Finland.______For transparency, this episode has been sponsored by TILT.______⭐️ ABOUT THE SPEAKERAino Kalervo is the Chief Operating Officer of TILT Biotherapeutics, responsible for fundraising and business development. She has also served as the president of TILT’s US affiliate since 2022. Prior to joining TILT, she worked for Sanofi and the French therapeutic vaccine company Theravectys.🔗 LINKS MENTIONED- TILT Biotherapeutics’ website: https://tiltbio.com/- TILT’s Series B round: https://tiltbio.com/userassets/uploads/2025/05/TILT-Series-B-press-release-May-2025.pdf- Marina Udier, Nouscom 🇨🇭 | Cancer Vaccines, Neoantigens | E21 - Flot.bio: https://flot.bio/episode/marina-udier-nouscom-cancer-vaccines/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/aino-kalervo-tilt-immunotherapy/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:01:44] Inside TILT’s $25M series B round[00:04:04] Multi-action oncolytic viruses[00:10:54] Learning from their peers[00:14:07] Phase 1 for melanoma[00:21:14] Collaborations and competitors[00:23:17] From Helsinki to global trials[00:33:03] Finland’s biotech ecosystem[00:39:00] Aino Kalervo’s personal path[00:45:43] Quickfire